Emily von Scheven, MD, MAS

My long-term goal is to improve the care and outcomes of children with rheumatic diseases. My research has focused on defining and improving outcomes in pediatric-onset Lupus, evaluating and treating childhood osteoporosis and addressing the transition needs of patients as they transition from pediatric to adult providers. I have experience conducting single-center and multi-center studies of various designs, including cohort studies, RCTs, focus groups, and consensus work.
Education
Master's of Advanced Studies, 2004 - Epidemiology & Biostatistics, UCSF
Fellowship, 1995 - Pediatric Rheumatology, Children's Hospital of Philadelphia
Residency, 1992 - Pediatrics, Children's National Medical Center
M.D., 1989 - School of Medicine, Pennsylvania State University
Websites
Publications
  1. Children with enthesitis-related arthritis could benefit from treatments targeted for adults with spondyloarthritis.
  2. Engaging patients and parents to improve mental health intervention for youth with rheumatological disease.
  3. Research Questions that Matter to Us: priorities of young people with chronic illnesses and their caregivers.
  4. New Medications Are Needed for Children With Juvenile Idiopathic Arthritis.
  5. Identifying clinically meaningful severity categories for PROMIS pediatric measures of anxiety, mobility, fatigue, and depressive symptoms in juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus.
  6. US Adult Rheumatologists' Perspectives on the Transition Process for Young Adults With Rheumatic Conditions.
  7. Prioritized Agenda for Mental Health Research in Pediatric Rheumatology from the Childhood Arthritis and Rheumatology Research Alliance Mental Health Workgroup.
  8. Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte.
  9. Distal His----Arg mutation in bovine myoglobin results in a ligand binding site similar to the abnormal beta site of hemoglobin Zurich (beta 63 His----Arg).
  10. Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus.
  11. Gaps in Mental Health Care for Youth With Rheumatologic Conditions: A Mixed Methods Study of Perspectives From Behavioral Health Providers.
  12. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
  13. Autoimmune haemolytic anaemia and autoimmune thrombocytopenia in childhood-onset systemic lupus erythematosus: updates on pathogenesis and treatment.
  14. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.
  15. Final adult height of patients with childhood-onset systemic lupus erythematosus: a cross sectional analysis.
  16. Adverse pregnancy outcomes in adolescents and young women with systemic lupus erythematosus: a national estimate.
  17. The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans: Toward Comparative Effectiveness in the Pediatric Rheumatic Diseases.
  18. Malignancy in Pediatric-onset Systemic Lupus Erythematosus.
  19. Clinical characteristics of children with membranous lupus nephritis: the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
  20. Malignancy incidence in 5294 patients with juvenile arthritis.
  21. Identifying Targets for Improving Mental Healthcare of Adolescents with Systemic Lupus Erythematosus: Perspectives from Pediatric Rheumatology Clinicians in the United States and Canada.
  22. Practice patterns and approach to kidney biopsy in lupus: a collaboration of the Midwest Pediatric Nephrology Consortium and the Childhood Arthritis and Rheumatology Research Alliance.
  23. Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment.
  24. Educational and vocational outcomes of adults with childhood- and adult-onset systemic lupus erythematosus: nine years of followup.
  25. Atypical cases of scleroderma en coup de sabre.
  26. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.
  27. Cancer risk in childhood-onset systemic lupus.
  28. Perception of transition readiness and preferences for use of technology in transition programs: teens' ideas for the future.
  29. Inactive disease and remission in childhood-onset systemic lupus erythematosus.
  30. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus.
  31. Use of atorvastatin in systemic lupus erythematosus in children and adolescents.
  32. Self-management skills in adolescents with chronic rheumatic disease: A cross-sectional survey.
  33. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus.
  34. Adult outcomes of childhood-onset rheumatic diseases.
  35. Vitamin D supplementation in the pediatric rheumatology clinic.
  36. Assessment of bone remodelling in childhood-onset systemic lupus erythematosus.
  37. Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.
  38. Toward the development of criteria for global flares in juvenile systemic lupus erythematosus.
  39. What's new in paediatric SLE?
  40. Teaching musculoskeletal physical diagnosis using a web-based tutorial and pathophysiology-focused cases.
  41. Relation of body fat indexes to vitamin D status and deficiency among obese adolescents.
  42. The challenges of transferring chronic illness patients to adult care: reflections from pediatric and adult rheumatology at a US academic center.
  43. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort.
  44. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus.
  45. Pediatric bone density and fracture.
  46. Does calcium supplementation increase bone mineral density in healthy children?
  47. Epstein-Barr virus-associated B cell lymphoproliferative disease in a child with neonatal-onset multisystem inflammatory disease.
  48. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies.
  49. Variable deficits of bone mineral despite chronic glucocorticoid therapy in pediatric patients with inflammatory diseases: a Glaser Pediatric Research Network study.
  50. Neonatal-onset multisystem inflammatory disorder: the emerging role of pyrin genes in autoinflammatory diseases.
  51. Association between beta2-glycoprotein I gene polymorphisms and pediatric SLE and antiphospholipid antibodies.
  52. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus.
  53. Back to school on APS: rethinking the risk of recurrent stroke in children.
  54. Thrombosis and pediatric Wegener's granulomatosis: acquired and genetic risk factors for hypercoagulability.
  55. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome.
  56. Systemic lupus erythematosus and antiphospholipid syndrome in children and adolescents.
  57. Pediatric Wegener's granulomatosis complicated by central nervous system vasculitis.
  58. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
  59. Clinical characteristics of antiphospholipid antibody syndrome in children.
  60. Analysis of HLA-DMB mutants and -DMB genomic structure.
  61. Hygienic problems in anaesthesia and intensive care therapy.
  62. [Chemical disinfection of anaesthetic equipment (author's transl)].